COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Bhoori, Sherrie; Rossi, Roberta; Citterio, Davide; Mazzaferro, Vincenzo

doi:10.1016/s2468-1253(20)30116-3

Cited by 237 publications

(313 citation statements)

References 5 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, we did not see a higher mortality in solid organ transplant recipients with COVID-19 and comorbidities appear to play a significant role in the outcome of COVID-19 in this subpopulation, as recently suggested by others. 5 Finally, a better understanding of the pathophysiology of the disease may improve our tailoring of immunomodulation in this specific setting.…”

Section: Clinical Outcome In Solid Organ Transplant Recipients With Cmentioning

confidence: 99%

Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience

Travi

Rossotti

Merli

et al. 2020

American Journal of Transplantation

View full text Add to dashboard Cite

Section: Clinical Outcome In Solid Organ Transplant Recipients With Cmentioning

confidence: 99%

Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience

Travi

Rossotti

Merli

et al. 2020

American Journal of Transplantation

View full text Add to dashboard Cite

“…However, it is a common assumption that immunocompromised patients are at increased risk of developing severe COVID-19. To challenge this assumption, a report from Italy (25) showed that 3 out of 111 liver transplant recipients who passed away due to COVID-19 had received their transplants 10 years prior to death. Interestingly, these patients were stable with very low trough concentrations of calcineurin inhibitors in plasma.…”

mentioning

confidence: 99%

COVID-19: an Immunopathological View

Kadkhoda

2020

mSphere

View full text Add to dashboard Cite

Since its emergence in December 2019, it took only a couple of months for an outbreak of the novel coronavirus disease 2019 (COVID-19) to be declared a pandemic by the World Health Organization (WHO). This along with the highly infectious nature of the disease and the associated mortality call for particular attention to the underlying (immuno)pathomechanism(s). The latter will inform case management and vaccine design. Unravelling these mechanisms can assist basic scientists, laboratory medicine practitioners, clinicians, public health practitioners, funding agencies, and health care policymakers in responding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

show abstract

“…For our patient, the course of disease was moderate and elaborated biomarker analysis was not conducted although that might be useful to potentially predict severe outcome (10). Preliminary data from Lombardy, Italy did not indicate an increased risk of severe COVID-19 in liver transplants in immunosuppression and reported a low mortality rate of 3% in long-term liver transplant recipients (11).…”

Section: Discussionmentioning

confidence: 85%

Recovery of moderate COVID-19 disease in a liver transplant recipient on continued immunosuppression

Mathiasen

Karlsen

Ott

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundThe global outbreak of severe acute respiratory syndrome coronavirus 2 has had an enormous impact on the world. It remains unclear to what extent liver transplant recipients should be considered at a higher risk of severe disease due to the limited data available.Case presentationWe describe a moderate course of COVID-19 in a patient who underwent a liver transplant two years earlier due to Budd-Chiari syndrome. She presented with malaise, headache, dry cough and fever for four days. Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection, oxygen therapy was given for a single night and the patient gradually recovered with supportive care only.ConclusionsWith this case report, we demonstrate that liver transplantation and immunosuppression is not necessarily associated with severe COVID-19 disease and emphasize that more information on this matter is urgently required. Withdrawal of immunosuppressive therapy could be associated with a higher mortality.

show abstract

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Cited by 237 publications

References 5 publications

Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience

Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience

COVID-19: an Immunopathological View

Recovery of moderate COVID-19 disease in a liver transplant recipient on continued immunosuppression

Contact Info

Product

Resources

About